Data on Influenza A Virus Discussed by Researchers at Ohio State University (Evaluation of Efficacy of Surface Coated versus Encapsulated Influenza Antigens in Mannose-Chitosan Nanoparticle-Based Intranasal Vaccine in Swine).

Researchers at Ohio State University have developed and characterized an intranasal vaccine platform using adjuvanted nanoparticulate delivery of swine influenza A virus (SwIAV). The vaccine, which employed whole inactivated H1N2 SwIAV as an antigen and STING-agonist ADU-S100 as an adjuvant, demonstrated high loading efficacy and non-cytotoxic properties suitable for intranasal vaccination. In a pig challenge trial, the intranasal vaccine induced cross-reactive sIgA antibodies in the respiratory tract and reduced viral replication in the nasal cavity. This novel vaccine platform shows potential effectiveness for pig immunization and represents a significant advancement in swine influenza vaccine design. [Extracted from the article]